Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (181-190 of 232) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|September 14, 2020
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
JNCI Cancer Spectrum|January 28, 2025
Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivorsYuhan Huang, Marilyn L Kwan, Susan R Heckbert, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Journal of the National Cancer Institute|March 12, 2025
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivorsYuhan Huang, Marilyn L Kwan, Susan R Heckbert, et al.
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Pageof 24

Showing results (181-190 of 232) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|September 14, 2020
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
JNCI Cancer Spectrum|January 28, 2025
Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivorsYuhan Huang, Marilyn L Kwan, Susan R Heckbert, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Journal of the National Cancer Institute|March 12, 2025
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivorsYuhan Huang, Marilyn L Kwan, Susan R Heckbert, et al.
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Pageof 24